Skip to main content

Table 2 Annual Worsening Rate (AWR)

From: IGF-1 in Friedreich’s Ataxia – proof-of-concept trial

FRDA patients

N

Annual worsening rate

CI 95%

Baseline – 3rd four-month period (AWR)

5

-0.40 ± 0.83

-1.28 to 0.48

Control

99

2,05 ± 1,23

1,58 to 2,52